Navigation Links
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Date:3/13/2008

Data Suggest Majority of Pompe Patients May Be Amenable to Chaperone

Therapy

CRANBURY, N.J., March 13 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present positive results from an ex vivo response study and three Phase 1 studies of AT2220 (1-deoxynojirimycin HCl), Amicus' compound in development for the treatment of Pompe disease, at the American College of Medical Genetics (ACMG) Annual Meeting from March 12-16 in Phoenix, AZ. The results of the ex vivo response study along with the previously reported results of the Phase 1 studies support moving into Phase 2 trials in the first half of 2008.

Ex Vivo Response Study data

Interim data will be presented from an ex vivo response study designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells derived from these samples were then tested to determine whether treatment with AT2220 caused an increase in the level of GAA. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels, including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T>G. It has been reported that more than 80% of Caucasian adult Pompe patients have at least 1 copy of this common splicing mutation.

Phase 1 AT2220 data

A total of 72 healthy volunteers were treated in three double-blind, placebo-controlled, dose escalation Phase 1 studies designed to evaluate the safety, tolerability and pharmacokinetics of AT2220. Across all three studies, AT2220 was shown to be generally safe and well tolerated at all doses. The
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
2. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today ... Logo - ... "Our new corporate identity signifies our transformation into ... first predictive analytics platform for patent claim validity." ... launch of the proprietary AIA Shield™ platform, the Company commenced ...
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
(Date:8/28/2015)... ANDOVER, Massachusetts and LONDON , ... driven approach seamlessly ... health continuum improving outcomes and ... Philips  (NYSE: PHG AEX: PHIA) today announced its presence ... its latest cardiology solutions, including Heart Model A.I. , EchoNavigator ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... are adulterated and misbranded; safety and efficacy not established , ... SILVER SPRING, ... the U.S. Food and Drug Administration, U.S. Marshals today seized ... Quality Monitor devices, as well as component parts used in the ...
... July 27 Volcano Corporation (Nasdaq: VOLC ) stated today ... it by St. Jude Medical in federal district court in Delaware ... and looks forward to vindicating its rights in court. , ... The Complaint filed today has nothing ...
Cached Medicine Technology:Federal Agents Seize FastSize Extenders and FastSize EQM™ Erectile Quality Monitors 2Volcano Will Strongly Defend Against St. Jude Lawsuit 2Volcano Will Strongly Defend Against St. Jude Lawsuit 3
(Date:8/28/2015)... , ... August 28, 2015 , ... An article ... local pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. ... permitting process tends to take several months, but the current process, having already gone ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
(Date:8/28/2015)... Neb. (PRWEB) , ... August 28, 2015 , ... Medical ... the 2015 Best Places to Work in Healthcare by Modern Healthcare and ... , Now in its eighth year, the Best Places to Work in ...
(Date:8/28/2015)... ... 2015 , ... SmartPractice Calendars afford dental offices ... contact information and logos, Calendars stand alone as functional brand-building giveaways ... mailings, thank you and welcome communications, and to complement statements and invoices. 2016 ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2
... threat, even without diet changes, study finds , , MONDAY, Dec. ... of the week is enough to undo metabolic syndrome, a ... stroke, a new study suggests. , "What we found was ... in improving metabolic syndrome risk," said study author Johanna L. ...
... researcher showed that acute and chronic constipation together accounted for ... children treated at one hospital. , The study also suggests ... when trying to determine the cause of abdominal pain in ... 962 children ages 4 to nearly 18, appear in the ...
... cardiac safety, TAMPA, Fla., Dec. 17 ... in electro-stun technology, today,announced a major research university ... Systems, S-200 projectile stun gun. Details of the,study ... meeting and/or,in a scientific journal. However, this study ...
... an effort to,help prepare today,s students to ... United Nations Environment Programme,s North,American Regional Office ... Day partnership and launched the International Children,s,Painting ... The International Children,s Painting Competition (ICPC) invites,elementary ...
... the nation in percentage of diabetes patients receiving,recommended ... claims, DALLAS, Dec. 17 The Dallas-Fort ... release of a new report on the,prevalence, costs ... 2 diabetes. The,Texas Type 2 Diabetes Report 2007 ...
... ATLANTA, December 17, 2007A new American Cancer Society report ... cancer cases and 7.6 million cancer deaths (about 20,000 ... comes from the first-ever Global Cancer Facts & Figures, ... of Facts & Figures publications. The report estimates that ...
Cached Medicine News:Health News:Moderate Exercise Cuts Risk of Metabolic Syndrome 2Health News:Moderate Exercise Cuts Risk of Metabolic Syndrome 3Health News:Constipation most common cause of children's abdominal pain 2Health News:Medical Study of Stinger S-200 Stun Gun Completed 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 3Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 4Health News:Dallas-Fort Worth Business Group on Health Releases Report on the State of Diabetes in Texas 2Health News:Dallas-Fort Worth Business Group on Health Releases Report on the State of Diabetes in Texas 3Health News:New report estimates 12 million cancer cases worldwide 2
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Natural eye color change for even the darkest of eyes....
Medicine Products: